Clinical Trial Update: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy

View source ↗

Summary

A clinical trial evaluating regorafenib in patients with gastrointestinal stromal tumors that progressed after standard therapy is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Gastrointestinal Stromal Tumors | Status: NO_LONGER_AVAILABLE